Mexico Flu Diagnostic and Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

The Mexico flu diagnostic and treatment market is projected to grow at a CAGR of 5.94% throughout the forecast period to reach US$374.253 million in 2027, from US$249.828 million in 2020.

Despite the presence of vaccination programs in the country, influenza still represents a significant disease burden in Mexico. The rising incidence of seasonal influenza across the country is significantly driving the market growth of the flu diagnostic and treatment market in Mexico. The flu diagnostic and treatment market in Mexico is anticipated to grow on account of the availability of modern healthcare in the country. The availability of influenza tests and influenza antiviral drugs to treat flu illness is also supporting the growth of the flu diagnostic and testing market in Mexico. The falling rate of vaccination in Mexico is another factor behind the rising incidence of influenza in the country, which, in turn, is boosting the market growth of the country’s flu diagnostic and treatment market. The rising prevalence of chronic diseases in Mexico also spurs the incidence of influenza across the country, which, in turn, is positively impacting the market growth of flu diagnostics and treatment. For instance, the Mexican Department of Epidemiology (InDRE) has authorized the sale of Co-Diagnostics, Inc.'s Logix SmartTM Influenza B/Influenza A/COVID-19 "ABC" Test in Mexico, the molecular diagnostics company announced in September 2021.

The Mexican flu diagnostic and treatment market is expected to grow due to the availability of OTC, low medication prices, and the tourism industry’s demand.

The growth of the Mexican flu diagnostic and treatment market is further boosted by the availability of OTC (over-the-counter) medicines for influenza-like illness (ILI). Moreover, it is illegal to bring some over-the-counter medicines into Mexico that are commonly used in the United States, including some allergy and sinus medications. In addition to the booming Mexican tourism industry, the rising influx of international tourists will boost the purchase of OTC medicines for influenza-like illnesses (ILI), which, in turn, will propel the market growth of flu diagnostic and treatment market.           

Product offering

• F. Hoffmann-La Roche Ltd. provides the Cobas® SARS-CoV- 2 and Influenza A & B tests. The company claims that the test kit can differentiate between COVID-19 and Flu. The test only takes 20 mins with minimum cross-contamination and risk of exposure during testing with the closed-system design.
• Fujirebio markets the DiaPlexQ™ Flu A/B & SARS-CoV-2 Detection Kit for Influenza in Mexico. It is a single-use test kit used for the qualitative detection of HA gene from influenza A and B viral antigens and ORFla gene from COVID-19.

COVID-19 Insights

Since the healthcare sector was overburdened with COVID-19 patients, the diagnostics and therapeutics for influenza cases declined to affect the market potential in 2020. During the COVID-19 epidemic, the diagnostic and treatment market for flu saw a declining trend in 2020. Mexico took swift action to prevent the spread of COVID-19 and implemented a country-wide lockdown. Due to strict rules, the common flu, and respiratory diseases experienced a reduction in the overall number of cases. Public health measures further reduced the transmission of flu in Mexico. But, with the changing measure, and reopening of normal business activities, influenza cases are surging in Mexico further helping the flu diagnostic and treatment market to grow.

Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory

Quidel Corporation

Thermo Fisher Scientific Inc.

F. Hoffmann-La Roche Ltd

3M

Co-Diagnostics, Inc.